You are here

SYNTHETIC VACCINES: TEST OF CONCEPTS AND APPLICATION TO RIFT VALLEY FEVER VIRUS

Award Information
Agency: Department of Defense
Branch: Army
Contract: N/A
Agency Tracking Number: 9951
Amount: $396,732.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 1991
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
19 Firstfield Rd
Gaithersburg, MD 20878
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Marc S Collett
 (301) 590-2622
Business Contact
Phone: () -
Research Institution
N/A
Abstract

USE OF SYNTHETIC PEPTIDES, COMPRISING BOTH B AND T CELL DETERMINANTS, IS BEING CONSIDERED A VIABLE APPROACH TO VACCINE DEVELOPMENT. WE WILL EXPLORE THE SUITABILITY OF THIS STRATEGY EMPLOYING RIFT VALLEY FEVER VIRUS (RVFV) AS THE STUDY MODEL. THE IMMUNOGENICITY OF SYNTHETIC PEPTIDES REPRESENTING SEVERAL PREVIOUSLY IDENTIFIED B CELL ANTIGENIC DETERMINANTS ON THE G2 GLYCOPROTEIN OF RVFV WILL BE EVALUATED IN FOUR STRAINS OF MICE DIFFERING IN H-2 HAPLOTYPE. A PEPTIDE SHOWING LOW IMMUNOGENICITY IN AT LEAST SOME MOUSE STRAINS WILL BE SELECTED FOR FURTHER STUDY. THE EFFECT OF KNOWN HELPER T CELL EPITOPES ON THE IMMUNOGENICITY OF THIS B EPITOPE PEPTIDE WILL THEN BE ESTABLISHED. FINALLY, HELPER T CELL SITE PREDICTIVE ALGORITHMS WILL BE TESTED FOR THEIR ABILITY TO IDENTIFY DETERMINANTS FROM THE GLYCOPROTEIN G2 SEQUENCE CAPABLE OF OVERRCOMING THE NONRESPONSIVENESS TO THE ABOVE B CELL EPITOPE. THESE STUDIES WILL EVALUATE SEVERAL CONCEPTS CENTRAL TO SYNTHETIC VACCINE DEVELOPMENT, AND IF VALIDATED, WILL ADVANCE THEIR APPLICATION TOWARD SUCH A VACCINE FOR RVFV.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government